Biolojic Design announced preclinical data for BD200, a multibody-drug conjugate targeting Trop-2 and Nectin-4, showing superior uptake and cytotoxicity compared to approved single-target drugs. BD200 demonstrated strong anti-tumor activity across multiple cancer models and in resistance settings where other ADCs failed. The company expects to enter clinical trials in the second half of 2026.

Teva Pharmaceuticals announced the launch of Home Ground™ Schizophrenia Community, a free online platform designed to support people living with schizophrenia and their care partners. The platform provides peer-driven resources, symptom tracking tools, emotional wellness support, and community events to address social isolation, which affects over 75% of people with psychotic disorders. The initiative was developed in collaboration with patients, care partners, and mental health advocacy groups.

Teva Pharmaceuticals, Direct Relief, and the National Association of Free and Charitable Clinics announced a second round of $75,000 grants to each of 11 free and charitable clinics across Alabama, Mississippi, and Texas to expand mental health services. In 2025, these programs reached over 57,000 people with mental health services and conducted nearly 6,000 depression and anxiety screenings. The initiative, now in its fourth year with $4 million in total funding since 2022, has demonstrated significant impact in addressing mental health access barriers in underserved communities.

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Viatris trades at a significant discount despite generating a 13.5% free cash flow yield and $2.2 billion in annual FCF. With a $650 million cost savings program launching in 2026, six regulatory decisions expected, and two Phase 3 assets with blockbuster potential, the stock trades 17% below peer-average EV/EBITDA. The company's differentiated specialty pipeline leverages its unmatched global distribution infrastructure across 40 countries and 165 markets, positioning it for genuine inflection in 2026 with projected first year of top-line growth since formation.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating osteoporosis and related bone conditions across all indications. Additionally, the company's proposed biosimilar candidate to Xolair (omalizumab) for allergic asthma and other conditions received filing acceptance from both the U.S. FDA and European EMA. These milestones advance Teva's Pivot to Growth strategy and expand its biosimilars portfolio.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet) biosimilar for treating various bone diseases, and acceptance of regulatory filings for an omalizumab biosimilar candidate by both FDA and EMA. These milestones represent significant progress in Teva's 'Pivot to Growth' strategy to establish itself as a leading biopharmaceutical company with a competitive biosimilar portfolio.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating various bone diseases, and acceptance of regulatory filings for its omalizumab biosimilar candidate to Xolair by both FDA and EMA. These approvals represent significant progress in Teva's 'Pivot to Growth' strategy to expand its biosimilar portfolio.

The 20th annual BIO-Europe Spring conference will take place in Lisbon, Portugal from March 23-25, 2026, attracting over 3,700 attendees from 2,000+ companies. The event expects over 20,000 one-to-one meetings and will feature key sessions on therapeutic landscapes, dealmaking strategies, and a startup pitch competition, with virtual partnering extending through April 1.

Billionaire Stanley Druckenmiller's Duquesne Family Office reduced positions in two high-performing stocks during Q4: cutting Teva Pharmaceutical by 65% and Taiwan Semiconductor by 29% after both stocks doubled. Meanwhile, Druckenmiller made a $301 million investment in the State Street Financial Select Sector SPDR ETF (XLF), making it his fund's second-largest holding, signaling potential optimism about the U.S. economy and financial sector prospects.

Teva Pharmaceuticals and Blackstone Life Sciences announced a $400 million strategic funding agreement spread over four years to support the clinical development of duvakitug, a human monoclonal antibody targeting TL1A for treating ulcerative colitis and Crohn's disease. Blackstone will be eligible for regulatory and commercial milestones plus royalties on worldwide sales. The partnership supports Teva's Pivot to Growth strategy and complements Teva's existing co-development agreement with Sanofi.

The author explains why he avoids investing in Teva Pharmaceutical despite recognizing its opportunities. While Teva's traditional generic drug business is lucrative, increased competition has eroded profits. The company's pivot toward complex generics and original drug development introduces higher risk in a highly competitive sector. The author cites concerns about Teva's ability to pivot if its drug pipeline underperforms, contrasting it with larger competitors like Pfizer that have greater resources to adapt.